Case Study · Multiple Sclerosis / mRNA Vaccine Response
How AcceleTrial identified specialist MS sites with the right patient profile for a niche mRNA vaccine response trial, with documents collected at 50% the standard rate.
The Challenge
Finding sites with the right combination of MS expertise and access to vaccine-naive patients for an mRNA trial required a precision approach that traditional site identification methods could not deliver quickly enough.
The sponsor needed 10 clinical sites with access to vaccine-naive MS patients, a specialized sub-population requiring both MS clinical expertise and specific patient history criteria.
The team needed to communicate with a large volume of clinical sites and execute CDAs and Feasibility Questionnaires on an accelerated schedule, with no room for slow document cycles.
Sites needed to be activated quickly and efficiently to exceed the sponsor's targeted timelines. For a novel mRNA study with a niche patient group, every lost week created compounding risk.
The Solution
Using AcceleTrial, LINEA System identified 12 sites with specific MS clinical expertise and the right patient access profile. The platform collected all necessary study documents at a 50% faster rate than standard timelines.
LINEA provided key contributing clinical sites and investigators evaluated against a rigorous set of qualification criteria, ensuring each site was genuinely prepared to enroll the right patients for this novel mRNA trial.
Outcomes
12 specialist MS sites with vaccine-naive patient access delivered against a target of 10, exceeding the request on first delivery.
All necessary study documents collected at 50% the standard timeline through AcceleTrial's automated workflow.
7 LINEA-sourced sites selected for inclusion in the mRNA vaccine response study from the 12 identified.
LINEA identified 20% more sites than the sponsor's requirement, providing a qualified reserve in a narrow patient population.
Get the Full Story
Get the one-page PDF summary or request a personalized demo using your protocol and therapeutic area.